Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Marine lipids, particularly omega-3 polyunsaturated fatty acids such as EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) derived from fish oil and other marine sources, have been investigated for their potential role in supporting cognitive function and treating dementia, including Alzheimer's disease. Scientific interest stems from the observation that DHA is a major structural component of neuronal membranes and is involved in neuroprotection, anti-inflammatory processes, and synaptic function.

Several epidemiological studies have suggested that higher dietary intake of marine-derived omega-3 fatty acids is associated with a reduced risk of cognitive decline and dementia. Some randomized controlled trials (RCTs) have found modest benefits of omega-3 supplementation on cognitive function in individuals with mild cognitive impairment (MCI), but results in established dementia, especially Alzheimer's disease, are mixed or show only minimal improvement. The largest RCTs generally report little to no significant benefit of marine lipid supplementation in slowing cognitive decline in people with established dementia.

Meta-analyses conclude that omega-3 supplementation may have a preventive effect if started before significant neurodegeneration occurs, but evidence for efficacy in treating established dementia is limited. Overall, marine lipids are used based on a plausible biological rationale and some supportive data, but their effectiveness in dementia treatment is not robustly established, leading to a moderate evidence rating.

More about Marine lipid
More about Dementia

Other ingredients used for Dementia

Other health conditions supported by Marine lipid

Products containing Marine lipid